Children's Oncology Group clinical trial pipeline

10 trials changed in the last 30 days: 3 stopped, 4 with notable changes, 3 with minor changes only.

1. Stopped

   New Combination of Anti-cancer Drugs in Patients Newly Diagnosed…New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

   Trial terminated

   Sponsor's reason: Drug supply issues

   Also in this update: Study completion date changed from estimate of Aug 19, 2027 to Sep 22, 2026

   Children's Oncology Group·Phase 2/3· NCT06820957· Registry history of NCT06820957 on ClinicalTrials.gov (opens the registry)

   Updated Oct 5, 2026

2. Stopped

   123I-MIBG and 18F-MFBG Imaging · Newly Diagnosed, High Risk…123I-MIBG and 18F-MFBG Imaging · Newly Diagnosed, High Risk Neuroblastoma

   Withdrawn before enrolling

   Sponsor's reason: Other - Protocol moved to Withdrawn

   Children's Oncology Group·Phase 2· NCT06858501· Registry history of NCT06858501 on ClinicalTrials.gov (opens the registry)

   Updated Sep 16, 2026

3. Stopped

   Enable Electronic Laboratory Data Transfer From Participating…Enable Electronic Laboratory Data Transfer From Participating Institutions to MediData/RAVE

   Trial terminated

   Sponsor's reason: Funding for the project ended and all analyses have been completed

   Also in this update: Final enrollment: 46 participants (planned 118)

   Children's Oncology Group·Not specified· NCT05020951· Registry history of NCT05020951 on ClinicalTrials.gov (opens the registry)

   Updated Sep 14, 2026

4. Notable

   Somatic Mosaicism in Twins Discordant for Childhood Cancer

   Primary completion pushed from Jun 30, 2026 to Jun 30, 2027

   Children's Oncology Group·Not specified· NCT06054295· Registry history of NCT06054295 on ClinicalTrials.gov (opens the registry)

   Updated Oct 1, 2026

5. Notable

   New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be…New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

   Primary endpoint(s) modified

   Children's Oncology Group·Phase 2· NCT04195399· Registry history of NCT04195399 on ClinicalTrials.gov (opens the registry)

   Updated Oct 1, 2026

6. Notable

   How to Safely Guide Surgery for Melanoma and Similar Skin Tumors…How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

   Phase changed: not applicable → Phase 2

   Also in this update: Trial sites expanded: 5 → 13 locations

   Children's Oncology Group·Phase 2· NCT07621614· Registry history of NCT07621614 on ClinicalTrials.gov (opens the registry)

   Updated Sep 24, 2026

7. Notable

   Veliparib, Radiation Therapy, and Temozolomide · Newly Diagnosed…Veliparib, Radiation Therapy, and Temozolomide · Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

   Sponsor changed: National Cancer Institute (NCI) to Children's Oncology Group

   Also in this update: Completion pushed from Oct 16, 2026 to Aug 20, 2027

   Children's Oncology Group·Phase 2· NCT03581292· Registry history of NCT03581292 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.